D. Rauch

发表

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).

R. Winterhalder, G. Bodoky, K. Zaugg, 2018, European journal of cancer.

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

E. Kimby, M. Ghielmini, H. Hawle, 2019, Blood.

Capecitabine with Weekly Paclitaxel for Advanced Breast Cancer: A Phase I Dose-Finding Trial

C. Rochlitz, S. Aebi, P. Brauchli, 2004, Oncology.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial

H. Groen, V. Torri, U. Dafni, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

U. Dafni, R. Stahel, S. Peters, 2017, The Lancet. Respiratory medicine.

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.

J. Machiels, T. Gauler, B. Melichar, 2019, Oral oncology.

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

J. Bernhard, K. Zaman, R. Winterhalder, 2016, BMC Cancer.

Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).

C. Mamot, R. Cathomas, P. Fustier, 2013, Clinical lung cancer.

BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients

D. Betticher, T. Pabst, Y. Banz, 2017, Annals of Hematology.

Quality of Life in Second‐Line Treatment of Metastatic Castration‐Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry

D. Betticher, C. Rentsch, F. Stenner, 2017, Clinical genitourinary cancer.

Final Results of the Randomized Phase II NorCap‐CA223 Trial Comparing First‐Line All‐Oral Versus Taxane‐Based Chemotherapy for HER2‐Negative Metastatic Breast Cancer

A. Barnadas, A. Chan, Michiel Botha, 2017, Clinical breast cancer.

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).

J. Dufour, G. Bodoky, M. Montemurro, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland

A. Goldhirsch, S. Gelber, A. Partridge, 2022, Journal of Cancer Survivorship.

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.

M. Ghielmini, S. Rondeau, G. Martinelli, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contemporary treatment patterns and survival of cervical cancer patients in Ethiopia

A. Jemal, N. Cihoric, I. Soldatovic, 2021, BMC Cancer.

Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).

T. Ruhstaller, M. Montemurro, P. Schneider, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy

D. Aebersold, P. Ghadjar, R. Giger, 2013, Strahlentherapie und Onkologie.

Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients.

M. Salzberg, C. Rochlitz, M. Borner, 2006, European journal of cancer.

Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients

D. Aebersold, O. Eliçin, R. Giger, 2018, Strahlentherapie und Onkologie.

The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research.

R. Herrmann, J. Bernhard, M. Borner, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Procholecystokinin as Marker of Human Ewing Sarcomas

J. Rehfeld, F. Nielsen, T. V. Hansen, 2004, Clinical Cancer Research.

1195OFINAL RESULTS OF THE SAKK 16/00 TRIAL: A RANDOMIZED PHASE III TRIAL COMPARING NEOADJUVANT CHEMORADIATION TO CHEMOTHERAPY ALONE IN STAGE IIIA/N2 NON-SMALL CELL LUNG CANCER (NSCLC).

R. Mirimanoff, R. Stupp, R. Stahel, 2014, Annals of Oncology.

Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).

R. Mirimanoff, R. Stupp, R. Stahel, 2013 .

Diagnosis and treatment outcomes for patients with lymphoma of the parotid gland

P. Ghadjar, D. Rauch, P. Zbären, 2013, The Laryngoscope.

Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers.

A. Goldhirsch, S. Gelber, R. Berardi, 2019, Breast.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

R. Mirimanoff, R. Stupp, R. Stahel, 2015, The Lancet.

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer

L. Bubendorf, D. Betticher, R. Cathomas, 2013, PloS one.

Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

L. Bubendorf, R. Stahel, S. Peters, 2015, Clinical lung cancer.

Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First‐Line Docetaxel: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (SAKK 08/11)

J. Bernhard, R. Winterhalder, S. Crabb, 2016, The Prostate.

Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis.

D. Aebersold, P. Ghadjar, O. Eliçin, 2016, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.

R. Stupp, L. Bubendorf, R. Stahel, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.

M. Ghielmini, S. Rondeau, T. Pabst, 2020, Blood advances.

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.

K. Harrington, N. Gibson, A. Psyrri, 2019, JAMA oncology.

CURRENT STATUS OF CLINICAL TRIALS IN ETHIOPIA:HOW MUCH IS DONE?

B. Jeremic, N. Cihoric, D. Rauch, 2018 .

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.

R. Herrmann, J. Bernhard, M. Borner, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

E. Kimby, M. Ghielmini, H. Hawle, 2016 .

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

E. Kimby, H. Hawle, S. Rondeau, 2014 .

Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity

D. Betticher, T. Pabst, B. Mueller, 2016, Leukemia & lymphoma.

Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.

D. Rossi, J. Passweg, T. Pabst, 2020, Blood advances.

Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK

C. Rochlitz, S. Aebi, P. Ballabeni, 2007, Oncology.

Breast cancer care in northern Ethiopia – cross-sectional analysis

N. Cihoric, D. Rauch, A. Tsikkinis, 2019, BMC Cancer.

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.

U. Dafni, R. Stahel, M. Guillot, 2021, Lung cancer.

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

R. Gelber, H. Gómez, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).

L. Bubendorf, R. Stahel, D. Betticher, 2012, Lung cancer.

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small‐cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial

R. Stahel, S. Peters, D. Betticher, 2017, Clinical lung cancer.

J. Bernhard, K. Zaman, R. Winterhalder, 2016, BMC Cancer.

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.

R. Winterhalder, G. Bodoky, F. Bosman, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Patterns of Cancer in University of Gondar Hospital: North-West Ethiopia

D. Rauch, B. Tefera, B. Abebe, 2018 .

Activity of Gemcitabine and Continuous Infusion Fluorouracil in Advanced Pancreatic Cancer

H. Friess, M. Büchler, C. Maurer, 2000, Oncology.

Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).

R. Winterhalder, G. Bodoky, F. Bosman, 2015 .

Capecitabine and Vinorelbine as First-Line Treatment in Elderly Patients (≥65 Years) with Metastatic Breast Cancer

B. Thürlimann, C. Rochlitz, P. Ballabeni, 2008, Oncology.